Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Everolimus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    314 result(s) found for: Everolimus. Displaying page 5 of 16.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-003403-39 Sponsor Protocol Number: CRAD001C2491 Start Date*: 2007-03-29
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Combination of antiangiogenic therapy using the mTOR-inhibitor RAD001 and low dose chemotherapy for locally advanced and/or metastatic pancreatic cancer – a dose finding study
    Medical condition: advanced and/or metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001407-11 Sponsor Protocol Number: Certican MHH PRTx01 Start Date*: 2006-07-18
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: A single center study investigating ciclosporine A microemulsion in combination with basiliximab and prednisolon and switch to low-dose ciclosporine A and everolimus without steroids in the prevent...
    Medical condition: Kidney transplantation after end stage renal failure
    Disease: Version SOC Term Classification Code Term Level
    9.0 10014647 LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004459-38 Sponsor Protocol Number: TREACE_2015 Start Date*: 2016-02-24
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: EXPLORATIVE STUDY TO IDENTIFY A SPECIFIC TRANSCRIPTOMIC PROFILE FOR PREDICTING THE MAJOR ADVERSE EFFECTS ASSOCIATED WITH CERTICAN (EVEROLIMUS) IN RENAL TRANSPLANT RECIPIENTS: A PHARMACOGENOMIC APPR...
    Medical condition: kidney transplant
    Disease: Version SOC Term Classification Code Term Level
    21.0 10042613 - Surgical and medical procedures 10038533 Renal transplant PT
    21.0 10042613 - Surgical and medical procedures 10038533 Renal transplant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-002220-34 Sponsor Protocol Number: EVEROSTAT Start Date*: 2005-10-03
    Sponsor Name:Fundación Investigación y Desarrollo Área Cardiovascular & Dr. Javier Segovia, Unidad de Trasplante
    Full Title: Estudio prospectivo y aleatorizado para la evaluación del efecto del everolimus en la progresión clínica y por ecografía intracoronaria de la enfermedad vascular del injerto cardíaco (EVI) establec...
    Medical condition: Trasplante cardíaco
    Disease: Version SOC Term Classification Code Term Level
    10050432
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000269-12 Sponsor Protocol Number: SF-RSM-HM-1 Start Date*: 2006-10-05
    Sponsor Name:Sociedad Madrileña de Nefrología (SOMANE)
    Full Title: Estudio multicéntrico, aleatorizado, abierto, de 2 años de seguimiento para evaluar el efecto de la retirada de inhibidores de la calcineurina y la introdicción temprana de everolimus, sobre la fun...
    Medical condition: Trasplante renal, realizado tres meses antes del inicio del estudio, y que se encuentra en fase de mantenimiento.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001502-10 Sponsor Protocol Number: GCTSK002 Start Date*: 2011-09-28
    Sponsor Name:National Cancer Institute
    Full Title: Phase II study of Everolimus in refractory testicular germ cell cancer.
    Medical condition: refractory metastatic germ cell tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2008-006055-52 Sponsor Protocol Number: CRAD001JDE15T Start Date*: 2009-01-09
    Sponsor Name:Charité - University Hospital of Berlin
    Full Title: Everolimus (RAD001) in combination with intravenous carboplatin in taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer
    Medical condition: Breast cancer is the most prevalent malignancy in women and metastatic breast cancer is a leading cause of mortality, accounting for more than 400,000 deaths annually worldwide. Even though anthrac...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017477-38 Sponsor Protocol Number: MEK112110 Start Date*: Information not available in EudraCT
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An Open-Label, Dose-Escalation, Phase IB/ II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination with Oral Evero...
    Medical condition: Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    12.1 10059515 Non-small cell lung cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000771-42 Sponsor Protocol Number: CRAD001ASE01 Start Date*: 2007-10-20
    Sponsor Name:Novartis Pharma Services
    Full Title: A controlled randomized open-label multicentre study evaluatiing if early conversion to everolimus (Certican) from cyclosporine (Neoral) in de novo renal transplant receipients can improve long-ter...
    Medical condition: Renal Transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-000860-90 Sponsor Protocol Number: CRAD001M2304 Start Date*: 2013-02-14
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A three-arm, randomized, double-blind, placebo-controlled study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC)...
    Medical condition: Refractory partial-onset seizures associated with tuberous sclerosis complex (TSC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10045138 Tuberous sclerosis PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) NL (Completed) DE (Completed) HU (Completed) GB (Completed) BE (Completed) GR (Completed) DK (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004847-35 Sponsor Protocol Number: PredEver_first Start Date*: 2012-09-07
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first) - A prospective multicenterphase IIA study -
    Medical condition: chronic Graft versus Host Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10018799 GVHD LLT
    14.1 10021428 - Immune system disorders 10063109 Transfusion associated GVHD LLT
    14.1 10021428 - Immune system disorders 10068907 CGVHD LLT
    14.1 10021428 - Immune system disorders 10018653 Graft-versus-host disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001191-38 Sponsor Protocol Number: CRAD001HES01 Start Date*: 2013-08-21
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Multicentric, randomized, open-label, controlled study, of 12 months of follow-up to assess the effect in renal function of a immunosuppressive treatment based on tacrolimus minimization in combin...
    Medical condition: Asumiendo una mayor eficacia en la prevención del rechazo agudo en el brazo de everolimus con minimización de los niveles de tacrolimus, la hipótesis del presente ensayo es que la introducción de e...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-019484-10 Sponsor Protocol Number: E7080-G000-205 Start Date*: 2011-07-18
    Sponsor Name:Eisai Ltd
    Full Title: An open-label, multicenter Phase Ib/2 study of E7080 alone, and in combination with everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior VEGF-tar...
    Medical condition: Unresectable Advanced or Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038414 Renal cell carcinoma stage IV PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-000256-18 Sponsor Protocol Number: CRAD001N2202 Start Date*: 2013-07-25
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A single-arm, open label, multi-center phase II study investigating oral everolimus tablets with dose titration in pediatric patients with relapsed or refractory Hodgkin lymphoma
    Medical condition: relapsed or refractory Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020206 Hodgkin's disease PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013780-19 Sponsor Protocol Number: CRAD001AES07 Start Date*: 2010-02-18
    Sponsor Name:NOVARTIS FARMACÉUTICA S.A
    Full Title: Estudio multicéntrico, aleatorizado, abierto, de 24 meses de duración, con dos grupos paralelos, para comparar la eficacia de everolimus en la mejora del perfil cardiovascular en el régimen con AMF...
    Medical condition: Demostrar que el tratamiento inmunosupresor con everolimus (Certican®) tiene un impacto positivo en la enfermedad cardiovascular, una de las principales causas de morbilidad y mortalidad en los pac...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-006160-48 Sponsor Protocol Number: HE67/12 Start Date*: 2012-05-07
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: Phase II multicenter single-arm study evaluating the safety and efficacy of everolimus as a first-line treatment in newly-diagnosed patients with advanced GI neuroendocrine tumors.
    Medical condition: Well or moderately differentiated advanced (metastatic or unresectable) GI or pancreatic neuroendocrine tumors.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002866-19 Sponsor Protocol Number: CRAD001AIT25 Start Date*: 2011-07-25
    Sponsor Name:NOVARTIS FARMA
    Full Title: A 3-month, multicenter, randomized, open label study to evaluate the impact of early vs delayed introductioN of EVERolimus on WOUND healing in de novo kidney transplant recipients (NEVERWOUND study)
    Medical condition: Renal transplantation
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002198-37 Sponsor Protocol Number: ENHVIE Start Date*: 2016-09-19
    Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE - IDIBELL
    Full Title: A single-center, randomized, open-label, 12 months study, with two parallel group to compare the efficacy of everolimus combination + tacrolimus in regression of left ventricular hypertrophy vs tac...
    Medical condition: Left ventricular hypertrophy in renal transplant patients in the maintenance phase .
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10049773 Left ventricular hypertrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-006111-62 Sponsor Protocol Number: CRAD001JDE49 Start Date*: 2012-07-11
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination Wi...
    Medical condition: The trial aims to evaluate the efficacy, safety, quality of life and health resources in postmenopausal women with hormone receptor positive breast cancer progressing following prior therapy with N...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001798-26 Sponsor Protocol Number: PROMETE Start Date*: 2014-02-12
    Sponsor Name:CHU DE POITIERS
    Full Title: A multicenter, open-label, Prospective, randomized parallel group Phase III study investigating the benefit on Renal function of a CNI-free regimen with MyfOrtic® (mycophenolate sodium) and Certica...
    Medical condition: Kidney transplantation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 19:40:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA